Log in

NYSE:NVRONevro Competitors & Alternatives

$117.76
+0.06 (+0.05 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$116.54
Now: $117.76
$119.91
50-Day Range
$115.21
MA: $123.57
$129.85
52-Week Range
$60.51
Now: $117.76
$148.05
Volume324,062 shs
Average Volume386,468 shs
Market Capitalization$4.00 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.91

Competitors

Nevro (NYSE:NVRO) Vs. PODD, ABMD, HRC, PEN, NVCR, and TNDM

Should you be buying NVRO stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Nevro, including Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Novocure (NVCR), and Tandem Diabetes Care (TNDM).

Nevro (NYSE:NVRO) and Insulet (NASDAQ:PODD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Risk & Volatility

Nevro has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Insulet has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

97.4% of Nevro shares are owned by institutional investors. 7.6% of Nevro shares are owned by insiders. Comparatively, 1.1% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Nevro and Insulet's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94
Insulet$738.20 million17.19$11.60 million$0.191,058.47

Insulet has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Nevro and Insulet, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro04802.67
Insulet19902.42

Nevro presently has a consensus target price of $120.8333, indicating a potential upside of 2.61%. Insulet has a consensus target price of $192.8333, indicating a potential downside of 4.12%. Given Nevro's stronger consensus rating and higher probable upside, equities research analysts plainly believe Nevro is more favorable than Insulet.

Profitability

This table compares Nevro and Insulet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-21.36%-40.67%-18.52%
Insulet0.66%7.66%0.91%

Summary

Insulet beats Nevro on 9 of the 13 factors compared between the two stocks.

ABIOMED (NASDAQ:ABMD) and Nevro (NYSE:NVRO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Institutional and Insider Ownership

94.4% of ABIOMED shares are owned by institutional investors. Comparatively, 97.4% of Nevro shares are owned by institutional investors. 3.4% of ABIOMED shares are owned by insiders. Comparatively, 7.6% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ABIOMED and Nevro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ABIOMED24.14%18.51%16.31%
Nevro-21.36%-40.67%-18.52%

Earnings & Valuation

This table compares ABIOMED and Nevro's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ABIOMED$840.88 million14.13$203.01 million$4.7455.66
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94

ABIOMED has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than ABIOMED, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

ABIOMED has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for ABIOMED and Nevro, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ABIOMED14302.25
Nevro04802.67

ABIOMED presently has a consensus price target of $193.00, suggesting a potential downside of 26.85%. Nevro has a consensus price target of $120.8333, suggesting a potential upside of 2.61%. Given Nevro's stronger consensus rating and higher probable upside, analysts plainly believe Nevro is more favorable than ABIOMED.

Summary

ABIOMED beats Nevro on 9 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Nevro (NYSE:NVRO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Hill-Rom and Nevro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom00503.00
Nevro04802.67

Hill-Rom currently has a consensus price target of $126.20, suggesting a potential upside of 13.11%. Nevro has a consensus price target of $120.8333, suggesting a potential upside of 2.61%. Given Hill-Rom's stronger consensus rating and higher possible upside, equities research analysts clearly believe Hill-Rom is more favorable than Nevro.

Valuation & Earnings

This table compares Hill-Rom and Nevro's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.91 billion2.55$152.20 million$5.0821.96
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94

Hill-Rom has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Hill-Rom has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

85.7% of Hill-Rom shares are held by institutional investors. Comparatively, 97.4% of Nevro shares are held by institutional investors. 0.7% of Hill-Rom shares are held by insiders. Comparatively, 7.6% of Nevro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Hill-Rom and Nevro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom5.04%22.60%7.71%
Nevro-21.36%-40.67%-18.52%

Summary

Hill-Rom beats Nevro on 9 of the 14 factors compared between the two stocks.

Nevro (NYSE:NVRO) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Insider and Institutional Ownership

97.4% of Nevro shares are owned by institutional investors. Comparatively, 83.8% of Penumbra shares are owned by institutional investors. 7.6% of Nevro shares are owned by company insiders. Comparatively, 9.6% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Nevro and Penumbra, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nevro04802.67
Penumbra00503.00

Nevro currently has a consensus price target of $120.8333, suggesting a potential upside of 2.61%. Penumbra has a consensus price target of $194.00, suggesting a potential upside of 3.22%. Given Penumbra's stronger consensus rating and higher probable upside, analysts clearly believe Penumbra is more favorable than Nevro.

Valuation & Earnings

This table compares Nevro and Penumbra's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94
Penumbra$547.41 million12.04$48.46 million$0.98191.79

Penumbra has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nevro has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Profitability

This table compares Nevro and Penumbra's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nevro-21.36%-40.67%-18.52%
Penumbra7.04%5.72%4.28%

Summary

Penumbra beats Nevro on 11 of the 14 factors compared between the two stocks.

Novocure (NASDAQ:NVCR) and Nevro (NYSE:NVRO) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Risk and Volatility

Novocure has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Earnings & Valuation

This table compares Novocure and Nevro's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novocure$351.32 million17.34$-7,230,000.00($0.07)-866.43
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94

Novocure has higher earnings, but lower revenue than Nevro. Novocure is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Novocure and Nevro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novocure12502.50
Nevro04802.67

Novocure currently has a consensus price target of $79.00, indicating a potential upside of 30.26%. Nevro has a consensus price target of $120.8333, indicating a potential upside of 2.61%. Given Novocure's higher possible upside, analysts plainly believe Novocure is more favorable than Nevro.

Profitability

This table compares Novocure and Nevro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novocure2.34%4.39%1.94%
Nevro-21.36%-40.67%-18.52%

Insider & Institutional Ownership

69.2% of Novocure shares are owned by institutional investors. Comparatively, 97.4% of Nevro shares are owned by institutional investors. 5.6% of Novocure shares are owned by insiders. Comparatively, 7.6% of Nevro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Novocure beats Nevro on 9 of the 14 factors compared between the two stocks.

Tandem Diabetes Care (NASDAQ:TNDM) and Nevro (NYSE:NVRO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Earnings & Valuation

This table compares Tandem Diabetes Care and Nevro's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tandem Diabetes Care$362.30 million16.35$-24,750,000.00($0.22)-448.09
Nevro$390.26 million10.26$-103,690,000.00($3.37)-34.94

Tandem Diabetes Care has higher earnings, but lower revenue than Nevro. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.4% of Tandem Diabetes Care shares are held by institutional investors. Comparatively, 97.4% of Nevro shares are held by institutional investors. 6.0% of Tandem Diabetes Care shares are held by insiders. Comparatively, 7.6% of Nevro shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Tandem Diabetes Care has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Tandem Diabetes Care and Nevro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tandem Diabetes Care-4.22%-9.39%-5.51%
Nevro-21.36%-40.67%-18.52%

Analyst Recommendations

This is a summary of current recommendations and price targets for Tandem Diabetes Care and Nevro, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tandem Diabetes Care06602.50
Nevro04802.67

Tandem Diabetes Care currently has a consensus price target of $93.3077, suggesting a potential downside of 5.35%. Nevro has a consensus price target of $120.8333, suggesting a potential upside of 2.61%. Given Nevro's stronger consensus rating and higher probable upside, analysts clearly believe Nevro is more favorable than Tandem Diabetes Care.

Summary

Nevro beats Tandem Diabetes Care on 8 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Insulet logo
PODD
Insulet
1.4$201.11+3.2%$12.69 billion$738.20 million2,514.19
ABIOMED logo
ABMD
ABIOMED
1.3$263.84+3.3%$11.88 billion$840.88 million59.69
Hill-Rom logo
HRC
Hill-Rom
1.8$111.57+1.0%$7.43 billion$2.91 billion51.18Insider Selling
Penumbra logo
PEN
Penumbra
1.4$187.95+1.4%$6.59 billion$547.41 million172.43
Novocure logo
NVCR
Novocure
1.9$60.65+1.7%$6.09 billion$351.32 million673.96Analyst Upgrade
Tandem Diabetes Care logo
TNDM
Tandem Diabetes Care
1.3$98.58+0.3%$5.92 billion$362.30 million-298.72Analyst Report
Insider Selling
Globus Medical logo
GMED
Globus Medical
1.8$49.16+1.0%$4.80 billion$785.37 million33.90
Haemonetics logo
HAE
Haemonetics
1.6$92.56+3.1%$4.66 billion$988.48 million62.97Analyst Report
Insider Selling
Integra Lifesciences logo
IART
Integra Lifesciences
1.7$48.72+0.1%$4.13 billion$1.52 billion157.16Heavy News Reporting
ICU Medical logo
ICUI
ICU Medical
1.5$186.72+2.2%$3.89 billion$1.27 billion46.22Analyst Upgrade
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.2$21.45+8.0%$3.39 billion$4.11 million-18.03Analyst Report
Insider Selling
Irhythm Technologies logo
IRTC
Irhythm Technologies
1.4$113.50+1.0%$3.07 billion$214.55 million-51.83Analyst Downgrade
Insider Selling
Unusual Options Activity
NuVasive logo
NUVA
NuVasive
1.6$57.08+0.5%$2.93 billion$1.17 billion49.64
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.6$44.96+0.6%$2.49 billion$994.85 million-561.93
Inspire Medical Systems logo
INSP
Inspire Medical Systems
1.3$88.88+1.6%$2.37 billion$82.05 million-51.98Analyst Downgrade
Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
2.3$44.53+0.2%$1.88 billion$918.16 million66.46
AtriCure logo
ATRC
AtriCure
1.4$46.30+2.2%$1.86 billion$230.81 million-38.58Analyst Upgrade
Glaukos logo
GKOS
Glaukos
1.3$38.64+0.3%$1.71 billion$236.98 million-41.11
SWAV
Shockwave Medical
1.3$47.46+1.2%$1.51 billion$42.93 million-24.72
Luminex logo
LMNX
Luminex
1.2$32.84+2.5%$1.50 billion$334.64 million-218.92
SILK
Silk Road Medical
1.3$42.39+0.5%$1.33 billion$63.35 million-33.38Analyst Report
AXNX
Axonics Modulation Technologies
1.4$37.87+3.9%$1.31 billion$13.82 million-13.77
Atrion logo
ATRI
Atrion
1.0$648.04+0.2%$1.19 billion$155.07 million33.32
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$32.22+2.9%$1.14 billion$248.02 million-103.93
Cerus logo
CERS
Cerus
1.4$6.76+0.0%$1.11 billion$74.65 million-14.08Analyst Downgrade
Analyst Revision
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.2$14.93+0.1%$924.02 million$88.02 million-20.74Analyst Downgrade
Heavy News Reporting
VAPO
Vapotherm
0.9$41.35+1.4%$880.73 million$48.10 million-15.49Analyst Downgrade
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.6$40.87+0.1%$786.05 million$189.49 million99.68Analyst Upgrade
Orthopediatrics logo
KIDS
Orthopediatrics
1.3$44.11+0.0%$785.97 million$72.55 million-43.25
OraSure Technologies logo
OSUR
OraSure Technologies
1.3$12.02+6.5%$746.03 million$154.60 million60.10Analyst Downgrade
Cryolife logo
CRY
Cryolife
1.6$19.62+3.0%$740.47 million$276.22 million-150.92Analyst Report
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$32.19+0.5%$618.11 million$459.95 million-128.75Analyst Upgrade
SurModics logo
SRDX
SurModics
1.4$43.00+0.2%$585.05 million$100.08 million87.76
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.9$38.37+0.5%$544.78 million$114.51 million20.97Analyst Upgrade
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
2.1$26.35+0.4%$531.79 million$117.23 million30.29Analyst Downgrade
CODX
Co-Diagnostics
0.8$18.89+3.0%$518.66 million$220,000.00-57.24
SIBN
SI-Bone
1.5$16.11+0.9%$457.96 million$67.30 million-9.82Analyst Revision
Heavy News Reporting
Antares Pharma logo
ATRS
Antares Pharma
1.9$2.73+1.5%$451.98 million$123.86 million136.57
Intersect ENT logo
XENT
Intersect ENT
1.7$13.73+1.6%$447.04 million$109.14 million-8.80Analyst Upgrade
Analyst Revision
Heavy News Reporting
KRMD
Repro Med Systems
2.0$9.07+4.4%$393.95 million$23.16 million302.43Heavy News Reporting
AngioDynamics logo
ANGO
AngioDynamics
2.0$10.33+2.1%$388.67 million$359.48 million8.01
Cytosorbents logo
CTSO
Cytosorbents
1.5$9.96+0.1%$360.66 million$24.95 million-18.11Analyst Upgrade
Alphatec logo
ATEC
Alphatec
1.4$4.96+5.2%$317.68 million$113.43 million-4.35
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$86.38+2.7%$314.63 million$46.90 million21.92
Iradimed logo
IRMD
Iradimed
1.5$23.96+0.8%$288.72 million$38.52 million31.12Analyst Downgrade
SeaSpine logo
SPNE
SeaSpine
1.6$10.44+0.5%$284.43 million$159.08 million-5.02Analyst Downgrade
Analyst Revision
ICAD
iCAD
1.5$9.82+3.8%$224.55 million$31.34 million-8.85Analyst Downgrade
Liquidia Technologies logo
LQDA
Liquidia Technologies
2.1$7.79+6.3%$221.02 million$8.07 million-3.42Insider Buying
High Trading Volume
Pulse Biosciences logo
PLSE
Pulse Biosciences
2.2$10.50+2.7%$219.13 millionN/A-4.47
Accuray logo
ARAY
Accuray
1.5$2.17+1.8%$196.43 million$418.79 million108.55
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.